Literature DB >> 3418334

Gamma-vinyl GABA: comparison of neurochemical and anticonvulsant effects in mice.

R Bernasconi1, M Klein, P Martin, P Christen, T Hafner, C Portet, M Schmutz.   

Abstract

Biochemical and pharmacological effects of gamma-vinyl GABA (Vigabatrin, GVG), and irreversible enzyme-activated inhibitor of 4-aminobutyrate: 2-oxoglutarate aminotransferase (EC 2.6.1.19; GABA-T), were measured in mice. This anticonvulsant produced a time- and dose-dependent elevation of the GABA, phenylalanine and lysine contents of cortical tissue and simultaneously decreased glutamate, aspartate and alanine levels. In addition, GVG caused a biphasic change in glutamine concentrations (a decline 1-4 hours after administration, followed 20 hours later by an increase). Moreover, we found a new, as yet unidentified amino acid in the brain eluting with the same retention time as alpha-aminoadipic acid from an HPLC cation-exchange column. The level of this novel chemical entity was greatly increased by GVG 20 hours after injection of the drug. At all tested intervals between 1 and 60 hours after injection, GVG was ineffective against maximal electroshock. The GABA-T inhibitor dose-dependently protected mice against isoniazid-induced seizures, simultaneously causing an increase in brain GABA concentrations. However, this apparent correlation applied only until 4 hours after treatment. To better define the anticonvulsant profile of GVG, groups of mice were treated, 1, 2, 4, and 24 hours prior to challenge with convulsant doses of strychnine, pentetrazole (PTZ), and picrotoxin, and brain amino acid levels, including brain concentrations of GVG, were measured. In all instances, the time dependency of the anticonvulsant effects of GVG and of increases in brain GABA levels differed. Amino acid concentrations in animals treated only with GVG were similar to those in animals given GVG and a chemical convulsant. GVG showed no selectivity for seizures produced by impairment of GABA-ergic neurotransmission. Although GVG is an effective GABA-T inhibitor, it apparently affects several other pyridoxal-phosphate-dependent cerebral enzymes and/or interacts with other neurotransmitter systems as well.

Entities:  

Mesh:

Substances:

Year:  1988        PMID: 3418334     DOI: 10.1007/BF01243421

Source DB:  PubMed          Journal:  J Neural Transm            Impact factor:   3.575


  20 in total

Review 1.  New concepts on the mechanism of action of benzodiazepines.

Authors:  E Costa; A Guidotti; C C Mao; A Suria
Journal:  Life Sci       Date:  1975-07-15       Impact factor: 5.037

2.  gamma-Vinyl GABA: effects of chronic administration on the metabolism of GABA and other amino compounds in rat brain.

Authors:  T L Perry; S J Kish; S Hansen
Journal:  J Neurochem       Date:  1979-06       Impact factor: 5.372

Review 3.  The pharmacology of GABA-transaminase inhibitors.

Authors:  M G Palfreyman; P J Schechter; W R Buckett; G P Tell; J Koch-Weser
Journal:  Biochem Pharmacol       Date:  1981-04-15       Impact factor: 5.858

4.  Antiepileptic drug development: II. Anticonvulsant drug screening.

Authors:  R L Krall; J K Penry; B G White; H J Kupferberg; E A Swinyard
Journal:  Epilepsia       Date:  1978-08       Impact factor: 5.864

5.  Audiogenic seizure protection by elevated brain GABA concentration in mice: effects of gamma-acetylenic gaba and gamma-vinyl GABA, two irreversible GABA-T inhibitors.

Authors:  P J Schechter; Y Tranier; M J Jung; P Böhlen
Journal:  Eur J Pharmacol       Date:  1977-10-15       Impact factor: 4.432

6.  Dose pipecolic acid interact with the central GABA-ergic system?

Authors:  R Bernasconi; R S Jones; H Bittiger; H R Olpe; J Heid; P Martin; M Klein; P Loo; A Braunwalder; M Schmutz
Journal:  J Neural Transm       Date:  1986       Impact factor: 3.575

7.  Blockade of epileptic responses in the photosensitive baboon, Papio papio, by two irreversible inhibitors of GABA-transaminase, gamma-acetylenic GABA (4-amino-hex-5-ynoic acid) and gamma-vinyl GABA (4-amino-hex-5-enoic acid).

Authors:  B Meldrum; R Horton
Journal:  Psychopharmacology (Berl)       Date:  1978-09-15       Impact factor: 4.530

8.  Acute effects of sodium valproate and gamma-vinyl GABA on regional amino acid metabolism in the rat brain: incorporation of 2-[14C]glucose into amino acids.

Authors:  A G Chapman; K Riley; M C Evans; B S Meldrum
Journal:  Neurochem Res       Date:  1982-09       Impact factor: 3.996

9.  O-phthalaldehyde: fluorogenic detection of primary amines in the picomole range. Comparison with fluorescamine and ninhydrin.

Authors:  J R Benson; P E Hare
Journal:  Proc Natl Acad Sci U S A       Date:  1975-02       Impact factor: 11.205

10.  The specific protective effect of diazepam and valproate against isoniazid-induced seizures is not correlated with increased GABA levels.

Authors:  R Bernasconi; M Klein; P Martin; C Portet; L Maître; R S Jones; V Baltzer; M Schmutz
Journal:  J Neural Transm       Date:  1985       Impact factor: 3.575

View more
  13 in total

1.  The effects of vigabatrin on electrophysiology and visual fields in epileptics: a controlled study with a discussion of possible mechanisms.

Authors:  I F Comaish; C Gorman; G M Brimlow; C Barber; G M Orr; N R Galloway
Journal:  Doc Ophthalmol       Date:  2002-03       Impact factor: 2.379

Review 2.  Vigabatrin. A review of its pharmacodynamic and pharmacokinetic properties, and therapeutic potential in epilepsy and disorders of motor control.

Authors:  S M Grant; R C Heel
Journal:  Drugs       Date:  1991-06       Impact factor: 9.546

Review 3.  Adverse reactions to new anticonvulsant drugs.

Authors:  I C Wong; S D Lhatoo
Journal:  Drug Saf       Date:  2000-07       Impact factor: 5.606

4.  Evaluation of the sedative and anticonvulsant properties of three Cameroonian plants.

Authors:  Fleur Clarisse Moto Okomolo; Joseph Tanyi Mbafor; Elisabeth Ngo Bum; Nadège Kouemou; Antoine Kavaye Kandeda; Emmanuel Talla; Théophile Dimo; Alice Rakotonirira; Silvère Vincent Rakotonirira
Journal:  Afr J Tradit Complement Altern Med       Date:  2011-07-03

5.  Differential effects of vigabatrin, gamma-acetylenic GABA, aminooxyacetic acid, and valproate on levels of various amino acids in rat brain regions and plasma.

Authors:  W Löscher; D Hörstermann
Journal:  Naunyn Schmiedebergs Arch Pharmacol       Date:  1994-03       Impact factor: 3.000

6.  Clinical profile of vigabatrin as monotherapy for treatment of infantile spasms.

Authors:  Jason T Lerner; Noriko Salamon; Raman Sankar
Journal:  Neuropsychiatr Dis Treat       Date:  2010-11-08       Impact factor: 2.570

7.  Biphasic action of vigabatrin on cortical epileptic after-discharges in rats.

Authors:  Pavel Mares; Romana Slamberová
Journal:  Naunyn Schmiedebergs Arch Pharmacol       Date:  2004-02-07       Impact factor: 3.000

8.  Treatment of epilepsy: the GABA-transaminase inhibitor, vigabatrin, induces neuronal plasticity in the mouse retina.

Authors:  Qing-Ping Wang; Firas Jammoul; Agnès Duboc; Jie Gong; Manuel Simonutti; Elisabeth Dubus; Cheryl M Craft; Wen Ye; José A Sahel; Serge Picaud
Journal:  Eur J Neurosci       Date:  2008-04       Impact factor: 3.386

Review 9.  Newer antiepileptic drugs. Towards an improved risk-benefit ratio.

Authors:  P N Patsalos; J W Sander
Journal:  Drug Saf       Date:  1994-07       Impact factor: 5.606

Review 10.  The neuropharmacology of the ketogenic diet.

Authors:  Adam L Hartman; Maciej Gasior; Eileen P G Vining; Michael A Rogawski
Journal:  Pediatr Neurol       Date:  2007-05       Impact factor: 3.372

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.